Skip to content

Here’s Why Mesoblast Share Price Plunged Over 30% Today

Camelliah Ramleh
Camellia Ramleh trader
Updated 11 Aug 2020

Open Demo Account YOUR CAPITAL IS AT RISK. 68% OF RETAIL CFD ACCOUNTS LOSE MONEY

Shares of Mesoblast Limited (ASX: MSB) plunged more than 30% on Tuesday after the Food and Drug Administration (FDA) questioned the evidence of sufficient benefit in the treatment of pediatric patients.

new-recommended-broker-banner

The U.S. regulator released two reports yesterday in relation to Mesoblast’s application for the approval of a stem cell treatment for children with a specific inflammatory condition. 

Mesoblast’s trial results have successfully reached the primary endpoint of a 28-day overall response rate in patients at 69.1%. The treatment has already received a green light from health authorities in Japan. 

The FDA advisory committee is scheduled to meet on Thursday to discuss whether additional clinical trials are required. 

Mesoblast share price plunges on FDA reports August 2020

Mesoblast share price plunged over 30% on the news to 3.36, just a day after it logged a 6-year high at 4.88.

Camelliah Ramleh
Camellia started her career in finance as an Islamic corporate banker at a Japanese mega bank, and later a Director at a London-based award winning hedge fund manager.